Sandoz (Japan)

Company snapshot

Sandoz is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 colleagues of 100 nationalities work together to ensure over one billion patients are reached by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 medicines addresses

• 3 approved product(s) across US/EU regulatory metadata.
• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Sandoz (Japan). Not investment advice.

• Peer + 0 momentum

  Regeneron UK

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Sandoz (Japan).

1. Jun 8, 2026 Clinical update

   SAN-1138 — Phase 3

2. Jun 8, 2026 Clinical update

   Olaparib tablets, 150 mg — Phase 1

3. Jun 8, 2026 Clinical update

   JPB898 (Induction and Maintenance) — Phase 3

4. Jun 8, 2026 Clinical update

   GME751 — Phase 1

View all clinical trial activity →

• What is Sandoz (Japan)?

  Sandoz Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Melanoma, Ovarian Cancer, Asthma. NovaPharmaNews links 4 clinical program(s), 8 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and US

• Is Sandoz (Japan) publicly traded?

  Sandoz (Japan) appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Sandoz (Japan) develop or market?

  We link 22 drug profile(s) where Sandoz (Japan) is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/sandoz-pharmaceuticals-d-d#company-drugs.

• What are the latest developments for Sandoz (Japan)?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Sandoz (Japan) focus on?

  Sandoz (Japan) focuses on Melanoma, Ovarian Cancer, Asthma based on our analysis of their pipeline programs and drug development activities.